Lupin has received tentative approval from the US FDA for its generic version of an HIV drug, to be manufactured at its Nagpur facility. Shares of Lupin Ltd ended lower on Wednesday (September 24) by 0.80% at ₹1,991 on the NSE.
Lupin has received tentative approval from the US FDA for its generic version of an HIV drug, to be manufactured at its Nagpur facility. Shares of Lupin Ltd ended lower on Wednesday (September 24) by 0.80% at ₹1,991 on the NSE.